[Ciprofloxacin and antibacterial therapy of respiratory tract infections].
Fluoroquinolones are present considered as an important independent group of chemotherapeutics within the class of quinolones, DNA-gyrase inhibitors characterized by high clinical efficacy and numerous indications, and clinical efficacy and humerous indications, and are known as a serious alternative to other highly efficient broad spectrum antibiotics. Significant clinical experience is accumulated with respect to ciprofloxacin, one of the first agents of the group up to date used clinically. In spite of the negative tendencies in development and distribution of antibiotic resistance, ciprofloxacin remains valid as an alternative drug in the treatment of many infections of various localization. Ciprofloxacin is one of the most useful agents in step-by-step or combined antibacterial therapy. Its us is substantiated by convincing microbiological, pharmacokintic and pharmacoeconomic reasons.
Ivanov
D V
DV
Budanov
S V
SV
D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy*; D002939:Ciprofloxacin / Q000494:pharmacology / Q000627:therapeutic use*; D024841:Fluoroquinolones / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D012140:Respiratory Tract Diseases / Q000188:drug therapy* / Q000382:microbiology; D059005:Topoisomerase II Inhibitors
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D059005:Topoisomerase II Inhibitors; D002939:Ciprofloxacin